Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 13/20 | 0.63 |
| ▸ | PRKCI | P41743 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2946255 | 0.94 | TBXAS1 (0.67) | TBXAS1 | |
| SCHEMBL15901891 | 0.92 | TBXAS1 (0.70) | TBXAS1 | |
| SCHEMBL15657210 | 0.92 | TBXAS1 (0.70) | TBXAS1 | |
| SCHEMBL2518958 | 0.92 | TBXAS1 (0.70) | TBXAS1 | |
| Hydrochloric Acid SCHEMBL15436986 | 0.91 | TBXAS1 (0.68) | TBXAS1 | |
| Iodide SCHEMBL810562 | 0.91 | TBXAS1 (0.68) | TBXAS1 | |
| SCHEMBL574077 | 0.88 | — | — | |
| Iodide SCHEMBL28622555 | 0.86 | TBXAS1 (0.54) | TBXAS1PRKCIALDH1A1 | |
| Hydrochloric Acid SCHEMBL15436959 | 0.86 | TBXAS1 (0.54) | TBXAS1ALDH1A1 | |
| Bromide SCHEMBL27752371 | 0.86 | TBXAS1 (0.54) | TBXAS1PRKCIALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0000951-B1 | PHARMACEUTICAL FORMULATIONS COMPRISING 1-SUBSTITUTED IMIDAZOLES, 1-SUBSTITUTED IMIDAZOLES AND 1-SUBSTITUTED IMIDAZOLES FOR USE IN THE TREATMENT OR PROPHYLAXIS OF THROMBO-EMBOLIC DISORDERS | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-05-23 | — | — | EP | claimed |
| US-4284641-A | ANTITHROMBOEMBOLIC AGENT | BURROUGHS WELLCOME CO. (US) | 1981-08-18 | — | — | US | claimed |
| EP-0000951-A1 | Pharmaceutical Formulations comprising 1-substituted imidazoles, 1-substituted imidazoles and 1-substituted imidazoles for use in the treatment or prophylaxis of thrombo-embolic disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1979-03-07 | — | — | EP | claimed |
| US-20240034899-A1 | CURABLE COMPOSITION | TOKYO OHKA KOGYO CO., LTD. (JP) | 2024-02-01 | — | — | US | disclosed |
| CN-117467307-A | curable composition | 东京应化工业株式会社 | 2024-01-30 | — | — | CN | disclosed |
| US-20230159593-A1 | CYCLOSPORINE ANALOGUES | UCL BUSINESS LTD (GB) | 2023-05-25 | — | — | US | disclosed |
| US-20230159593-A1 | CYCLOSPORINE ANALOGUES | UCL BUSINESS LTD (GB) | 2023-05-25 | — | — | US | disclosed |
| US-20230159593-A1 | CYCLOSPORINE ANALOGUES | UCL BUSINESS LTD (GB) | 2023-05-25 | — | — | US | disclosed |
| EP-4149555-A1 | CYCLOSPORINE ANALOGUES | UCL Business Ltd (GB) | 2023-03-22 | — | — | EP | disclosed |
| WO-2021229237-A1 | CYCLOSPORINE ANALOGUES | UCL BUSINESS LTD (GB) | 2021-11-18 | — | — | WO | disclosed |
| WO-2021229237-A1 | CYCLOSPORINE ANALOGUES | UCL BUSINESS LTD (GB) | 2021-11-18 | — | — | WO | disclosed |
| US-4731363-A | Thromboxane synthase inhibitors as insulin lowering agents and antiobesity agents | HOFFMANN-LA ROCHE INC. (US) | 1988-03-15 | — | — | US | disclosed |
| US-4591594-A | INSULIN LOWERING AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1986-05-27 | — | — | US | disclosed |
| US-4500540-A | DIETETICS | HOFFMANN-LA ROCHE INC. (US) | 1985-02-19 | — | — | US | disclosed |
| EP-0000951-B1 | PHARMACEUTICAL FORMULATIONS COMPRISING 1-SUBSTITUTED IMIDAZOLES, 1-SUBSTITUTED IMIDAZOLES AND 1-SUBSTITUTED IMIDAZOLES FOR USE IN THE TREATMENT OR PROPHYLAXIS OF THROMBO-EMBOLIC DISORDERS | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-05-23 | — | — | EP | disclosed |
| US-4284641-A | ANTITHROMBOEMBOLIC AGENT | BURROUGHS WELLCOME CO. (US) | 1981-08-18 | — | — | US | disclosed |
| EP-0000951-A1 | Pharmaceutical Formulations comprising 1-substituted imidazoles, 1-substituted imidazoles and 1-substituted imidazoles for use in the treatment or prophylaxis of thrombo-embolic disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1979-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159593-A1 | CYCLOSPORINE ANALOGUES | HAVCR2, CHP1, HLA-C | TBXAS1 2780/4885PRKCI 2367/4885ALDH1A1 3503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.